Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | HTR1B | P28222 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | HTR1E | P28566 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | RB1 | P06400 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189400 | 0.91 | RB1 (0.36) | CYP2C9PTGDRPTGDR2HTR4DRD2 | |
| SCHEMBL2188133 | 0.86 | KCNA3 (0.41) | CYP2C9PTGDRPTGDR2DRD2 | |
| SCHEMBL2187160 | 0.86 | CYP2C9 (0.37) | CYP2C9PTGDRPTGDR2HTR1BKCNQ2 | |
| SCHEMBL2191234 | 0.84 | PTGDR (0.36) | CYP2C9PTGDRPTGDR2HTR4HTR1A | |
| SCHEMBL2187311 | 0.83 | DRD2 (0.32) | CYP2C9PTGDRPTGDR2HTR1AHTR1B | |
| SCHEMBL2188978 | 0.78 | PSIP1 (0.33) | — | |
| SCHEMBL2190625 | 0.78 | PTGDR2 (0.41) | CYP2C9PTGDRPTGDR2CYP3A4 | |
| SCHEMBL12002811 | 0.77 | DRD4 (0.39) | CYP2C9PTGDRPTGDR2DRD2DRD4 | |
| SCHEMBL12002968 | 0.77 | AGTR2 (0.41) | CYP2C9PTGDRPTGDR2 | |
| SCHEMBL3663657 | 0.77 | PTGDR2 (0.56) | CYP2C9PTGDRPTGDR2HTR1AHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346865-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2011-07-27 | — | — | EP | disclosed |
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | CYP2C9 1320/4885PTGDR 3/4885PTGDR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.